Tatake Revati J, O'Neill Margaret M, Kennedy Charles A, Wayne Anita L, Jakes Scott, Wu Di, Kugler Stanley Z, Kashem Mohammed A, Kaplita Paul, Snow Roger J
Department of Cardiovascular Disease, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877, USA.
Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5. doi: 10.1016/j.bbrc.2008.09.087. Epub 2008 Oct 1.
We have identified two novel MEK5 inhibitors, BIX02188 and BIX02189, which inhibited catalytic function of purified, MEK5 enzyme. The MEK5 inhibitors blocked phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. The compounds also inhibited transcriptional activation of MEF2C, a downstream substrate of the MEK5/ERK5 signaling cascade, in a cellular trans-reporter assay system. These inhibitors offer novel pharmacological tools to better characterize the role of the MEK5/ERK5 pathway in various biological systems.
我们鉴定出了两种新型MEK5抑制剂,即BIX02188和BIX02189,它们可抑制纯化的MEK5酶的催化功能。在山梨醇刺激的HeLa细胞中,MEK5抑制剂可阻断ERK5的磷酸化,而不影响ERK1/2的磷酸化。在细胞转报告基因检测系统中,这些化合物还可抑制MEK5/ERK5信号级联反应的下游底物MEF2C的转录激活。这些抑制剂为更好地表征MEK5/ERK5通路在各种生物系统中的作用提供了新的药理学工具。